GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes
In this study of patients with T2D managed in routine clinical care, the use of GLP-1RAs was associated with lower rates of hyperkalemia and sustained RASi use compared with DPP-4i use. These findings suggest that GLP-1RA treatment may enable wider use of guideline-recommended medications and contribute to clinical outcomes in this population.
Authors
- Arvid Sjölander (ORCID: https://orcid.org/0000-0001-5226-6685)
- Anne‐Laure Faucon (ORCID: https://orcid.org/0000-0001-6716-1157)
- Edouard L. Fu (ORCID: https://orcid.org/0000-0002-9698-6825)
- Morgan E. Grams (ORCID: https://orcid.org/0000-0002-4430-6023)
- Juan Jesús Carrero (ORCID: https://orcid.org/0000-0003-4763-2024)
- Alessandro Bosi (ORCID: https://orcid.org/0000-0002-2806-0393)
- Yang Xu (ORCID: https://orcid.org/0000-0002-1074-608X)
- Tao Huang (ORCID: https://orcid.org/0000-0002-2098-1315)
Institutions
- Peking University (CN)
- Université Paris-Saclay (FR)
- Leiden University Medical Center (NL)
- Danderyds sjukhus (SE)
- Karolinska Institutet (SE)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- New York University (US)
Publication Details
- Journal
- JAMA Internal Medicine
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1001/jamainternmed.2024.3806
- Citations
- 6
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.51